- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02505568
A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease (BEGIN)
October 16, 2019 updated by: Janssen Korea, Ltd., Korea
An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease
The purpose of this study is to evaluate the efficacy of infliximab in induction regimen by assessing the mean decrease in Disease Activity Index for intestinal Behcet's disease (DAIBD) score of 20 or more in participants with active intestinal Behcet's disease who are refractory to conventional therapies.
Study Overview
Detailed Description
This is an open-label (all participants know the identity of the intervention), single arm, multicenter (when more than one hospital or medical school team work on a medical research study) study of Infliximab in participant with Moderate-to-Severe Refractory Intestinal Behcet's Disease.
The study consists of 3 Phases: Screening Phase (4 weeks), induction Phase for 8 weeks, and maintenance Phase for 24 weeks extending from Week 0 (baseline), and a safety Follow up visit (Week 36 or approximately 6 weeks after the last administration of study drug).
The duration of participation in the study for each participant is approximately 40 weeks.
The mean decrease in Disease Activity Index for intestinal Behcet's disease (DAIBD) score of 20 or more will be evaluated primarily.
Participants' safety will be monitored throughout the study.
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Busan, Korea, Republic of
-
Daegu, Korea, Republic of
-
Gangwon-do, Korea, Republic of
-
Gyeonggi-do, Korea, Republic of
-
Seoul, Korea, Republic of
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant had diagnosed of definite or probable intestinal Behcet's Disease (BD) prior to Screening
- Participant must have active intestinal BD, defined as; a) A baseline Disease Activity Index for intestinal Behcet's disease (DAIBD) score of greater than or equal to (>=) 40; b) Endoscopy with evidence of active intestinal BD (defined as ulcerations in the ileum and/or colon). The endoscopy must have occurred within 3 months prior to baseline
- Must either be currently receiving treatment with, or have a history of having failed to respond to, or tolerate, at least 1 of the following therapies as assessed by treating physician: oral corticosteroids, 6-mercaptopurine (6-MP), azathioprine (AZA), or methotrexate (MTX). a) Have no response to oral corticosteroids within the preceding 18 months; b) Have no response to 6-MP, AZA or MTX within the preceding 5 years
- Prior to the baseline, the following conditions must be met: a) If receiving 6-MP, AZA, or MTX must have been receiving it for at least 12 weeks, and the dose must be stable for at least 4 weeks; b) If 6-MP, AZA, or MTX have been recently discontinued, they must have been stopped for at least 4 weeks; c) If receiving oral 5-aminosalicylate (5-ASA) compounds or oral corticosteroids, the dose must have been stable for at least 2 weeks; d) If oral 5-ASA compounds or oral corticosteroids have been recently discontinued, they must have been stopped for at least 2 weeks; e) If receiving cyclosporine, the dose must have been stable for at least 6 weeks; f) If cyclosporine have been recently discontinued, they must have been stopped for at least 6 weeks
- Participant must be medically stable on the basis of physical examination, medical history, vital signs and 12-lead electrocardiogram (ECG) performed at Screening. If there are abnormalities, they must be consistent with the underlying illness in the study population, or the participant may be included only if the investigator judge the abnormalities from normal to be not clinically significant or to be appropriate. This determination must be recorded in the participant's source documents by the investigator
Exclusion Criteria:
- Participant has complications of intestinal BD such as symptomatic strictures or stenoses, short gut syndrome, central nervous system or vascular manifestation, or any other manifestation that might be anticipated to require surgery, could preclude the use of the DAIBD to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with infliximab
- Participant currently has or is suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks prior to baseline, or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery. Participants with active fistulas may be included if there is no anticipation of a need for surgery and there are currently no abscesses identified
- Participant has had any kind of bowel resection within 6 months or any other intra-abdominal surgery within 3 months prior to baseline
- Participant has a draining (ie, functioning) stoma or ostomy
- Participant has received any of the following prescribed medications or therapies within the specified period: a) Intravenous (IV) corticosteroids within 3 weeks prior to baseline; b) Other oral immunomodulatory agents (eg, 6-thioguanine (6-TG), tacrolimus, sirolimus, or mycophenolate mofetil) within 6 weeks prior to baseline; c) Non-biologic experimental or investigational agents within 4 weeks or within 5 half-lives of agent prior to baseline, whichever is longer; d) Other immunomodulatory biologic agents within 12 weeks or within 5 half-lives of agent prior to baseline, whichever is longer; e) Treatment with apheresis (eg, Adacolumn apheresis) or total parenteral nutrition (TPN) as a treatment for intestinal BD within 3 weeks prior to baseline
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Infliximab
Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 and will be evaluated for the induction phase at Week 8. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion at Week 14, Week 22, and Week 30 in the maintenance phase and will be evaluated at Week 32.
|
Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase.
Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Mean Decrease in Disease Activity Index for Intestinal Behcet's Disease (DAIBD) Score of 20 or More From Baseline at Week 8
Time Frame: Baseline and Week 8
|
The DAIBD will be assessed by collecting information on 8 different intestinal BD-related variables.
These 8 variables are: fever, abdominal mass, abdominal tenderness, intestinal complications, extraintestinal manifestations, general well-being, abdominal pain, and total number of liquid stools.
The last 3 variables are scored over 7 days by the participant on a diary card.
Abdominal pain will be measured using the 11-point numeric rating scale (NRS) to standardize the evaluation of pain and the result of 11-point NRS will be divided into 4 grades (none, mild, moderate, severe) to fill out the DAIBD.
where, None indicate 0; Mild indicate 1-3; Moderate indicate 4-6; Severe indicate 7-10.
|
Baseline and Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participant With Clinical Response by Disease Activity Index for Intestinal Behcet's Disease (DAIBD) at Week 8 and 32
Time Frame: At Week 8 and 32
|
The DAIBD will be assessed by collecting information on 8 different intestinal BD-related variables.
These 8 variables are: fever, abdominal mass, abdominal tenderness, intestinal complications, extraintestinal manifestations, general well-being, abdominal pain, and total number of liquid stools.
The last 3 variables are scored over 7 days by the participant on a diary card.
Abdominal pain will be measured using the 11-point numeric rating scale (NRS) to standardize the evaluation of pain and the result of 11-point NRS will be divided into 4 grades (none, mild, moderate, severe) to fill out the DAIBD.
where, None indicate 0; Mild indicate 1-3; Moderate indicate 4-6; Severe indicate 7-10.
|
At Week 8 and 32
|
Percentage of Participant With Crohn's Disease Activity Index (CDAI) 70 Response at Week 8 and 32
Time Frame: At Week 8 and 32
|
The CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables.
These 8 variables are: extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid stools, abdominal pain/cramping, and general well-being.
The last 3 variables are scored over 7 days by the participant on a diary card.
The CDAI 70-response is defined as a reduction from baseline in the CDAI score of greater than or equal to (>=) 70 points.
|
At Week 8 and 32
|
Change in Crohn's Disease Activity Index (CDAI) Score From Baseline at Week 8 and 32
Time Frame: Baseline, Week 8 and 32
|
The CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables.
These 8 variables are: extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid stools, abdominal pain/cramping, and general well-being.
The last 3 variables are scored over 7 days by the participant on a diary card.
|
Baseline, Week 8 and 32
|
Change in C -Reactive Protein (CRP) Concentration From Baseline at Week 8 and 32
Time Frame: Baseline, Week 8 and 32
|
The CRP has been demonstrated to be useful as a marker of inflammation in patients with inflammatory bowel disease (IBD).
In Behcet's Disease (BD), CRP concentrations in active disease participants have been found to be higher than those in inactive participants.
Blood samples for the measurement of CRP will be collected from all participants.
CRP will be assayed using a validated, high sensitivity CRP assay.
|
Baseline, Week 8 and 32
|
Change in Disease Activity Index for Intestinal Behcet's Disease (DAIBD) Score From Baseline at Week 32
Time Frame: Baseline and Week 32
|
The DAIBD will be assessed by collecting information on 8 different intestinal BD-related variables.
These 8 variables are: fever, abdominal mass, abdominal tenderness, intestinal complications, extraintestinal manifestations, general well-being, abdominal pain, and total number of liquid stools.
The last 3 variables are scored over 7 days by the participant on a diary card.
Abdominal pain will be measured using the 11-point numeric rating scale (NRS) to standardize the evaluation of pain and the result of 11-point NRS will be divided into 4 grades (none, mild, moderate, severe) to fill out the DAIBD.
where, None indicate 0; Mild indicate 1-3; Moderate indicate 4-6; Severe indicate 7-10.
|
Baseline and Week 32
|
Percentage of Participant With Clinical Remission (Disease Activity Index for Intestinal Behcet's Disease [DAIBD] Score less than or equal to [<=] 19) at Week 32
Time Frame: Week 32
|
The DAIBD will be assessed by collecting information on 8 different intestinal BD-related variables.
These 8 variables are: fever, abdominal mass, abdominal tenderness, intestinal complications, extraintestinal manifestations, general well-being, abdominal pain, and total number of liquid stools.
The last 3 variables are scored over 7 days by the participant on a diary card.
Abdominal pain will be measured using the 11-point numeric rating scale (NRS) to standardize the evaluation of pain and the result of 11-point NRS will be divided into 4 grades (none, mild, moderate, severe) to fill out the DAIBD.
where, None indicate 0; Mild indicate 1-3; Moderate indicate 4-6; Severe indicate 7-10.
|
Week 32
|
Period Needed to Reach Clinical Remission From Baseline at Week 32
Time Frame: Up to Week 32
|
The duration for participants required to reach clinical remission will be analysed.
|
Up to Week 32
|
Percentage of Participants With Mucosal Healing at Week 32
Time Frame: Week 32
|
Mucosal healing will be assessed using endoscopy (ileocolonoscopy) in consenting participants.
A video ileocolonoscopic examination will be performed according to the study reference manual provided to each site, at Screening and Week 32.
Investigators will measure the longest diameter (none, >= 1 centimeter [cm] to less than [<] 2 cm, >= 2 cm to < 3, >= 3 cm) of ileum and/or colon largest open ulcer and assess mucosal healing in 4 grades compared to the baseline according to the following; Grade 0: Mucosal healing; Grade 1: marked improvement (reduction to <= 1/4); Grade 2: improvement (reduction to <= 1/2 - > 1/4); Grade 3: no change or worse (reduction less than 1/2 or expansion).
|
Week 32
|
Number of Participants with Adverse Events (AEs) and Serious AEs
Time Frame: Up to Week 36
|
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Up to Week 36
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 22, 2015
Primary Completion (Actual)
July 13, 2018
Study Completion (Actual)
July 13, 2018
Study Registration Dates
First Submitted
June 29, 2015
First Submitted That Met QC Criteria
July 21, 2015
First Posted (Estimate)
July 22, 2015
Study Record Updates
Last Update Posted (Actual)
October 17, 2019
Last Update Submitted That Met QC Criteria
October 16, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Eye Diseases
- Genetic Diseases, Inborn
- Stomatognathic Diseases
- Mouth Diseases
- Uveitis, Anterior
- Panuveitis
- Uveitis
- Uveal Diseases
- Vasculitis
- Hereditary Autoinflammatory Diseases
- Skin Diseases, Genetic
- Skin Diseases, Vascular
- Behcet Syndrome
- Antirheumatic Agents
- Gastrointestinal Agents
- Dermatologic Agents
- Infliximab
Other Study ID Numbers
- CR107121
- REMICADEBEC3001 (Other Identifier: Janssen Korea, Ltd)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Behcet Disease
-
Novartis PharmaceuticalsCompleted
-
Yonsei UniversityRecruitingIntestinal Behcet DiseaseKorea, Republic of
-
Silk Road Therapies, Inc.Not yet recruitingBehcet Syndrome | Behcet DiseaseUnited States
-
Nobel PharmaceuticalsAinos, Inc. (f/k/a Amarillo Biosciences Inc.CompletedBehcet Syndrome | Behcet Disease | Mucocutaneous UlcerationTurkey
-
Novartis PharmaceuticalsCompletedBehcet DiseaseIndia, Turkey, Spain, Germany, Italy, France, Israel, Greece, Korea, Republic of, Hong Kong, United States, Egypt, Jordan, Singapore, Switzerland, Taiwan, Tunisia
-
Assiut UniversityNot yet recruitingBehcet Disease and Vascular Involvement
-
Assiut UniversityNot yet recruitingBehcet Disease and Vascular Affection
-
Peking Union Medical College HospitalNot yet recruitingAneurysm | Behcet Syndrome, Vascular TypeChina
-
Istanbul UniversityUnknownFMF | Behcet DiseaseTurkey
Clinical Trials on Infliximab
-
Onze Lieve Vrouwe GasthuisSanteonUnknown
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupTerminatedRheumatoid Arthritis
-
PfizerCompleted
-
Diakonhjemmet HospitalSouth-Eastern Norway Regional Health AuthorityCompletedRheumatoid Arthritis | Crohn's Disease | Ulcerative Colitis | Psoriatic Arthritis | Spondyloarthritis | Psoriasis ChronicNorway
-
Centre hospitalier de l'Université de Montréal...Ottawa Hospital Research Institute; Maisonneuve-Rosemont Hospital; Niagara Health... and other collaboratorsRecruiting
-
NYU Langone HealthWithdrawnInflammatory Bowel Disease
-
PfizerCompletedPsoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic PsoriasisJapan
-
European Organisation for Research and Treatment...CompletedMyelodysplastic SyndromesFrance, Belgium, Netherlands, Czech Republic, Italy, Germany
-
Janssen Research & Development, LLCJanssen Biologics BVCompletedUlcerative ColitisUnited States, France, United Kingdom, Belgium, Switzerland, Israel, Canada, Australia, Netherlands, New Zealand, Austria, Germany, Denmark, Czechia, Argentina
-
BiocadCompletedAnkylosing SpondylitisRussian Federation, Belarus